

Date: November 10, 2025

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051

SYMBOL: REMUS

Dear Sir/Madam,

Sub.: Intimation under Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation

In terms of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and our intimation dated November 06, 2025 regarding the Earnings Conference Call, we enclose herewith the Investor Presentation for H1 and FY26.

The aforesaid information is also being hosted on the Company's website at www.remuspharma.com.

You are requested to take the same on record.

Thanking you.

For, Remus Pharmaceuticals Limited

Deval Patel
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Encl: As Above

Remus Pharmaceuticals Limited


REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

Investor Presentation

November 2025

Snapshot



First-to-market products in **niche** therapies.



FY25 Return Ratios
RoE: **15.01%**
RoCE: **15.69%**
Net Debt to Equity: **0.05**



800+ registered products, **400+** products commercialized, **2000+** SKU's across **diverse therapeutic** segments



Over **150** distributors globally



Strong last-mile reach through **D2C + pharmacy channels** with high end product therapies



745+ dossier ready-to-file for various geographies



Asset-light model with scalable growth

Contents

1 Company Overview

2 Business Overview

3 Strategic Overview


4 Industry Overview

5 Financial Overview


Company Overview

- Remus Pharmaceuticals Limited, established in 2015, is one of the fastest growing pharmaceutical companies.
- Remus specializes in branding, marketing, and distribution of complex specialty and niche off patent formulations in various countries.
- The company has a diversified portfolio of 800+ approved products, 640+ MOH submitted/under evaluation products, and 745+ dossier registrations in major geographies.
- The product portfolio includes formulations across major therapeutic segments including oncology, cardiology, dermatology, diabetes etc.
- Remus works on an asset light model and a quick go-to market strategy of identifying off patent drugs with strong market potentials and undergoing R&D, dossier filings in relevant countries.
- Remus identifies and partners with CDMO and CMO sites that hold the appropriate accreditations as required by each country. We collaborate with over 30 global manufacturing partners.
- It has a strong marketing and distribution presence through local distributors in 40+ semi regulated markets of Latin America, Southeast Asia, Middle East, CIS and Africa, and also direct presence through established subsidiaries in Bolivia and Guatemala.
- The company is also expanding market reach through channel partners for large government and institutional tenders.
- Remus made a foray into the U.S. through the acquisition of Espee Global Holdings LLC in 2024, which operates as one of the largest distributor of Reference Listed Drugs (RLDs) and leader in sourcing and supplying hard-to-access REMS, specialty, orphan, and biosimilar drugs, serving 300+ customers across 30+ countries through an FDA-approved facility.

Revenues (INR Mn)



H1-FY26 Business Distribution



Key Milestones

- Initiated **exports** of finished formulations.
- Launched **global marketing** for Remus in semi-regulated & emerging markets.

Business Consolidation

2015

2017-2019

- Initiated presence in key **international markets** with focused product launches.
- Created a foundation for sustainable market penetration and regulatory approvals.
- Strengthened internal capabilities for exports.

Strategic Market Presence

2022

2023

- **Acquired Espee USA**
- **LATAM Expansion:** Deepened presence via incorporation in new countries and long-term alliances with local distributors.
- **Created Relius** brand for advance market development, specialty product launches, and last-mile distribution
- **Contractual partnerships** with sub-distributors and **major pharmacy chains** to optimize market reach and ensure sustainable growth in semi-regulated markets.

Strengthening LATAM Presence and Exploring New Markets

2024

2025
& Beyond

Collaboration & Partnership Building

- Forged partnerships with leading multinational pharmaceutical companies.
- Enhanced global **brand equity** and expanded distribution capabilities.
- Focused on compliance, **dossier development**, and registration in high-potential geographies.

Subsidiary Expansion

- Incorporated subsidiaries in **Bolivia** and **Guatemala** to localize market access.

Expansion & R&D Focus

- Targeting entry into 5+ new territories including **Eastern Europe, Africa, and ASEAN** regions.
- Participation in **Bolivia's** national tenders with a diversified portfolio of 10+ products.
- **R&D**-driven portfolio expansion.

Experienced Board of Directors



Mr. Arpit Shah
Managing Director

Mr. Arpit Shah, an Engineer from Gujarat University, instrumental to the business growth, handles business developments, alliance management, strategic decisions and portfolio expansion. He has worked for a large US based conglomerate.



Mr. Swapnil Shah
Chairman & Non- Executive, Non- Independent Director

Mr. Swapnil Shah holds a master's degree in Business Administration with a specialization in Finance & International Business from Hofstra University, New York, and a bachelor's degree in Chemical Engineering from Nirma University. He is involved in the business development and corporate strategy of the company. Prior to Remus, he worked as a Strategist in a NASDAQ listed Fintech company.



Ms. Roma Shah
Whole-time Director

Ms. Roma Shah holds a master's degree in Pharmaceutical Manufacturing from the USA and a bachelor's degree in Pharmacy from Gujarat University. She has been a strong pillar of the organization in the field of Regulatory, R&D, and strategic business support & management. She specializes in all critical technical aspects of the company.



Ms. Anar Shah
Non- Executive, Non- Independent Director

She is a silver medalist in Master of Business Administration with a specialization in Family Business & Entrepreneurship from Nirma University. She is a dentist by education and holds a bachelor's degree in Dental Surgery from BVDU Medical College. She is responsible for activities related to human resource development.



Mr. Vishrut Pathak
Non-Executive Independent Director

He holds a master's degree in Business Administration in International Finance from St. John's University and a PGD degree in Financial Statement Analysis from New York University. With over 20 years of rich experience in Investment Management and Corporate Finance, he mentors at EDII under the CrAdLE platform.



Ms. Sanjana Shah
Non-Executive Independent Director


Ms. Sanjana Shah, Non-Executive Independent Director of the company. She is a certified Chartered Accountant and holds a bachelor's degree in Law. In her 12 years of career in the field of Accounts and Financial Management, she has gained expertise in Mergers and Acquisitions, Financial Analysis, Credit Rating, and part of IR team.




Mr. Balwant Purohit
Non-Executive Independent Director

Mr. Balwant Purohit is a Non-Executive Independent Director of the company. He has extensive experience in hospitality management. His business caters to more than 600 clients annually across India under various catering and corporate events. He is result-oriented and resourceful with a proven ability to develop and strengthen management team to maximize efficiency.


Strong Global Presence



Business Overview



Product Registration & Regulatory Roadmap





Expert Regulatory Affairs Team

A highly skilled team of 30+ professionals, each specializing in key regions and complex products, including Oncology, Biosimilars, and Monoclonal Antibodies (MAB), Peptides.



Dossier Submission Excellence

Submitting 50+ dossiers monthly, with strong compliance to country-specific regulations.



Bioequivalence, Clinical, and Non- Clinical Research

Performing bioequivalence and clinical studies for compliance, and preparing non-clinical research to meet regulatory standards.



Dynamic & Adaptive Team

Dynamic and young team, technically skilled professionals and a business-focused group to stay closely aligned with market trends and demands.



Timely & Strategic Assessment

Conducting up-to-date studies to ensure products are market-ready and strategically aligned.



Quality Assurance & Control

Multi-step quality checks including IPQC, Batch Testing, Stability and Visual Inspections, Lab Testing, and Packaging Integrity to ensure safety and compliance.

B2B

Partner Driven Scalability

- End-to-end regulatory & commercial solutions for global partners
- Fast-track entry into **semi-regulated** & **emerging markets**
- In-house regulatory expertise ensuring swift market access
- Low R&D risk, faster commercialization timelines
- Strong scalability via partners' **marketing & distribution networks**
- Controlling high-quality dossiers, monetizable across markets
- **Low working capital**—no inventory or promotional spend
- Participating in **large government and institutional tenders**

Some of our niche and complex formulations



Amlodipine,
Valsartan and
Hydrochlorothiazide
Tablets 5mg, 160mg,
12.5mg



Eltrombopag Tablets
25mg




Bempedoic Acid
Tablets 180mg,
180+10mg




Palbociclib Capsules
125mg

Revenue (INR Mn) & Product Growth



Top Countries Growth




B2C

Brand-Led Profitability

- Operates under Relius brand via Bolivia & Guatemala subsidiaries
- Strong last-mile reach through **D2C + pharmacy channels**
- High safety & efficacy aligned with global standards
- Building brand equity via **trademark protection & market presence**
- Captures full value chain—**higher per-unit margins**
- Commands **premium pricing & differentiation** in commoditized markets

Revenue (INR Mn) & Product Growth



Some of our branded products



Sacubitril & Valsartan
tablets 50, 100, 200 mg



Iopromide Injections
300, 370 mg l/ml



Sodium Valproate
Tablets BP 500mg



Heparin Injection 25000IU



Carbidopa + Levopada
Tablets 25 mg + 250 mg



Iron Sucrose Injection
20mg/ml



Dexketoprofen
Injection 25 mg/ml



Lactulose Oral
Solution 10 mg – 15ml



Rivaroxaban
Tablets BP 10, 15, 20 mg



Cabergoline
Tablets USP 0.5 mg



Cefepime for
injection USP 1gm



Apixaban Tablets
2.5mg, 5mg

Integrated Product Snapshot

SKUs

Tablets
1076*



**Ointments,
Creams & Gels**
76*



Injectables
555*



**Inhalers/
Nebulizer**
27*



**Syrups & Oral
Suspensions**
75*



**Capsules (Hard Gel
& Soft Gel)**
237*




Other Products
115*



**Powder for
Injections**



Ophthalmic



Sachets




Biosimilars




Oncology

Registered Products



Therapeutic-Wise Registrations (%)



* Number of SKU's also Includes registered, filed and products under process of filing

Our Story – Connecting with the Community



**Brand Awareness Conference
with 55+ doctors and pharmacy
representatives - October 2024**



**Farmacorp Conference and
Training Event - December 2024**



**St. Agustin's Pharmacy
Chain Training - Jan 2025**



**Promotional event with Farma Elías
pharmacy chain - March 2025**



**Awareness Event for gynecologists,
general practitioners, and
hematologists in Oruro - March 2025**



**Training for Pharmacist in
Chavez Pharmacy – July
2025**



One of the world's largest pharmaceutical finished formulations specialty distributors and clinical trial service provider



Among the world's largest RLD distributors – Extensive global network and sourcing capabilities with an expertise in sourcing and supplying hard-to-get REMS, specialty, orphan, and biosimilar drugs.



Advanced Supply Chain – Customized dashboards, trend analysis, and complete logistics support for global, compliant deliveries.




High-ROE business – Generates strong returns on equity by combining operational efficiency with disciplined capital allocation, translating into higher profitability for shareholders.



Diverse Client Base – Trusted partner to 300+ largest global pharmaceutical conglomerates, including top generic pharma companies, biopharma innovators, R&D organizations, CMOs, CROs, and government agencies.

Strategic Overview

Key Strengths





Building strong direct-to-consumer (D2C) and pharmacy networks



600+ B2C products in development, Targeting 200+ B2C launches and over 2,000 new product filings



Training field force for ethical, doctor-driven promotion



New market entries: Bosnia, Ethiopia, Algeria, Kosovo, Mexico, Tanzania, etc.



Increase presence in developed markets – organic and acquisition route



Expand presence in semi-regulated and emerging markets by accelerating product registrations

Industry Overview





The Global Pharmaceutical formulations market was valued at USD \$1,511 Bn in FY2025, up from USD \$1,289 Bn in FY2022. It grew at a CAGR of approximately 5.4% between FY2022 and FY2025, driven by sustained demand in key therapy areas such as Oncology, Alimentary Tract & Metabolism, and Central Nervous System disorders. It is expected to grow with a steady CAGR of ~5.4% from FY2025 until FY2027 to reach USD \$1673 Bn.



Global Pharmaceutical Market by Region (in USD Bn) :- Between 2010-2020, Asia has grown exponentially and is now the heart of the global pharma industry. It is driving innovation, growth, and future development within the pharma sector. Globally, China and Japan are the second and third largest pharmaceutical markets.


Source: IQVIA, Frost & Sullivan Research and Analysis



Global Demand Drivers

- ◆ Increase in ageing population
- ◆ Increasing prevalence of chronic diseases
- ◆ Strong growth of global generic market
- ◆ Expansion of health insurance coverage

Global Pharmaceutical Market Growth (in USD Bn)



Indian Export Market



India ranks 3rd globally in pharmaceutical production by volume, known for its generic medicines and low-cost vaccines.



Exports reach 200+ countries, with the US as the largest market.



In FY24, exports stood at INR 2.43 lakh crore (USD 27.82 billion); FY25 (Apr-Jan) exports at INR 2.12 lakh crore (USD 24.26 billion).



India contributes ~20% of global generic drug exports.




Emerging markets such as Latin America and ASEAN showing double-digit growth in FY25, adding depth to India's export base.



Pharma exports expected to grow 10x–15x, reaching USD 350 billion by 2047.



Major Export Destination in India's Pharma Export in FY24 (%)




H1-FY26

Performance Highlights


Financial Highlights

Consolidated


Operational Revenue (INR Mn.)



EBITDA (INR Mn.)




PAT (INR Mn.)




Standalone


Operational Revenue (INR Mn.)



EBITDA (INR Mn.)



PAT (INR Mn.)



- Participated in the Nicaragua national tender and successfully secured two key product awards, strengthening its presence in the Central American region.
- Launched Rivastigmine Patch across multiple markets, marking Remus's expansion into a new therapeutic category.
- In Bolivia, subsidiary Relius Pharma SRL achieved successful commercial launches of Rivaroxaban 10 mg Tablet, Eltrombopag 25 mg Tablet, Carbidopa + Levodopa 250 mg + 25 mg Tablet, and Cefepime 1 gm Injection.
- Secured 37 new product approvals between April to September 2025, further strengthening regulatory footprint in the ASEAN region.
- Entered the Algerian market and initiated product registration activities, opening new growth opportunities in North Africa.
- Participated in national tenders with 20 products in each country; reflecting ongoing efforts to broaden tender market reach.

Half Yearly Standalone Income Statement

PARTICULARS (INR Mn.)	H1-FY26	H1-FY25	Y-O-Y	H2-FY25	H-O-H
Operational Revenue	469	377	24.4%	415	13.0%
Operating Expenses	321	265	21.1%	268	19.8%
EBITDA	148	112	31.4%	147	0.7%
EBITDA Margin (%)	31.56%	29.71%	185 Bps	35.42%	(386) Bps
Depreciation and Amortisation	13	7	85.7%	12	8.3%
Finance costs	2	2	-	2	-
Other Income	28	20	40.0%	10	NA
PBT	161	123	30.9%	143	12.6%
Tax Expense	41	31	32.3%	36	13.9%
PAT	120	92	30.9%	107	12.3%
PAT Margin (%)	25.59%	24.40%	119 Bps	25.78%	(19) Bps
Other Comprehensive Income	329	-	-	700	(53.0)%
Total Comprehensive Income	449	92	NA	807	(44.4)%
Diluted EPS	10.21	7.80	30.9%	9.09	12.3%

Half Yearly Consolidated Income Statement

PARTICULARS (INR Mn.)	H1-FY26	H1-FY25	Y-O-Y	H2-FY25	H-O-H
Operational Revenue	4,002	2,726	46.8%	3,478	15.1%
Operating Expenses	3,732	2,515	48.4%	3,232	15.5%
EBITDA	270	211	28.0%	246	9.8%
EBITDA Margin (%)	6.75%	7.74%	(99) Bps	7.07%	(32) Bps
Depreciation and Amortisation	13	7	85.7%	12	8.3%
Finance costs	7	8	(12.5)%	6	16.7%
Other Income	29	24	20.8%	26	11.5%
PBT	279	220	26.8%	254	9.8%
Tax Expense	63	41	53.7%	48	31.3%
PAT	216	179	20.9%	206	4.9%
PAT Margin (%)	5.40%	6.57%	(117) Bps	5.92%	(52) Bps
PAT Attributable to Owners of the Holding Company	175	131	33.6%	160	9.4%
Other Comprehensive Income	338	-	-	701	(51.8)%
Total Comprehensive Income	554	179	NA	907	(38.9)%
Diluted EPS	18.33	15.14	21.1%	17.46	5.0%

Historical Financials



Historical Consolidated Income Statement

PARTICULARS (INR Mn)	FY24	FY25	H1-FY26
Operational Revenue	2,129	6,204	4,002
Total Expenses	1,839	5,747	3,732
EBITDA	290	457	270
EBITDA Margins (%)	13.62%	7.37%	6.75%
Depreciation and Amortisation	11	19	13
Finance costs	5	15	7
Other Income	28	50	29
PBT	302	473	279
Tax	59	89	63
PAT	243	384	216
PAT Margins (%)	11.41%	6.19%	5.40%
Diluted EPS (INR)	42.97	65.21	18.33

Note: Financials for Subsidiaries set up/acquired during the relevant FY has been considered from the date of incorporation/date of acquisition, as applicable

Historical Consolidated Balance Sheet


ASSETS (INR Mn)	FY24	FY25	H1-FY26
Non-current assets			
a) Property, Plant & Equipment	21	49	70
b) Capital Work-In-Progress	-	-	2
c) Goodwill on Consolidation	87	87	87
d) Other Intangible Assets	2	-	-
e) Intangible Assets Under Development	-	1	1
f) Right to Use Assets	28	21	18
g) Financial Assets			
i) Non-Current Investments	1,044	1,861	2,245
ii) Long-term Loans and Advances	-	-	-
iii) Other Financial Assets	26	93	128
h) Deferred Tax Asset (net)	-	-	-
i) Other Non-current Asset	-	-	-
Total of Non-current assets	1,208	2,112	2,551
Current assets			
a) Inventories	431	516	1,055
b) Financial Assets			
i) Current Investments	1	-	131
ii) Trade Receivables	1,153	1,080	1,477
iii) Cash and Cash Equivalents	47	72	67
iv) Bank Balance other than above	91	9	12
v) Short-Term Loans And Advances	181	209	129
vi) Other Financial Assets	111	192	112
c) Current Tax Asset (net)	-	-	-
d) Other Current Assets	108	136	148
Total Current assets	2,123	2,214	3,131
Total Assets	3,331	4,326	5,682

EQUITY & LIABILITIES (INR Mn)	FY24	FY25	H1-FY26
Equity Share Capital	15	59	118
Reserve and Surplus	1,562	2,500	2,952
Total Equity	1,577	2,559	3,070
Non-Controlling Interest	175	267	310
Liabilities			
Non-current liabilities			
a) Financial Liabilities			
i) Long-Term Borrowings	30	33	54
ii) Lease Liabilities	22	16	11
b) Long -Term Provision	4	7	7
c) Deferred Tax Liabilities (Net)	112	229	281
d) Other Long-Term Liabilities	-	-	-
Total of Non-current liabilities	168	285	353
Current liabilities			
a) Financial Liabilities			
i) Short-Term Borrowings	86	175	87
ii) Lease Liabilities	5	5	8
iii) Trade Payables			
Total outstanding Dues for Creditors belongs to Micro & Small Enterprises	42	18	52
Total outstanding Dues for Creditors belongs other Micro & Small Enterprises	895	695	1,199
iv) Other Financial Liabilities	2	3	3
b) Other Current Liabilities	363	283	533
c) Short-Term Provision	4	8	12
d) Current Tax Liabilities (Net)	14	28	55
Total of Current liabilities	1,411	1,215	1,949
Total Liabilities	1,579	1,500	2,302
Total Equity & Liabilities	3,331	4,326	5,682


Note: Financials for Subsidiaries set up/acquired during the relevant FY has been considered from the date of incorporation/date of acquisition, as applicable

Standalone Financial Highlights


Revenue From Operation (INR Mn.)




EBITDA (INR Mn) & EBITDA Margins (%)




PAT (INR Mn) & PAT Margins (%)




Net Debt to Equity (X)



Trade Receivables Days




ROCE* (%) & ROE* (%)




*ROE & ROCE, Calculated on increased Capital base due to IND AS impact

Consolidated Financial Highlights


Revenue From Operation (INR Mn.)




EBITDA (INR Mn) & EBITDA Margins (%)




PAT (INR Mn) & PAT Margins (%)




Net Debt to Equity (X)



Working Capital Days




ROCE* (%) & ROE* (%)



*ROE & ROCE, Calculated on increased Capital base due to IND AS impact


1 Year Share Price Movement (Up to 30th September 2025)



Price Data (As on 30th September 2025)

Face value (INR)	10.0
Market Price (INR)	719.5
52 Week H/L (INR)	1,385.5 / 700.0
Market Cap (INR Mn.)	847.8
Equity Shares Outstanding (Mn.)	1.2
1 Year Avg. trading volume ('000)	6.3

Shareholding Pattern (As on 30th September 2025)



Remus Pharmaceuticals Ltd. Disclaimer:

The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation should not be construed as legal, tax, investment or other advice. This presentation is confidential, being given solely for your information and for your use, and may not be copied, distributed or disseminated, directly or indirectly, in any manner. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having been authorized by or on behalf of the Company.

Certain statements in this presentation may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal
Valorem Advisors
Tel: +91-22-4903 9500
Email: remus@valoremadvisors.com
Investor Kit: <http://valoremadvisors.com/remus>

Registered Office

1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli –Bopal Road, Ahmedabad,
Gujarat, India, 380054

CIN

L24232GJ2015PLC084536

ISIN

INE005T01011

 **NSE : REMUS**

Thank You